Abstract: Objective To study the clinical efficacy and safety of cool-tip microwave ablation combining transcatheter arterial chemoembolizatio （TACE） in treatment of patients with primary liver cancer （PLC）. Methods There were 72 patients with PLC in our series,and they were randomly divided into control group and observation group with 36 cases in each. The patients in the two groups were treated with cool-tip microwave ablation and TACE or TACE alone. The effective rate,two-year survival rate and serum alpha fetoprotein （AFP） reduction rate were evaluated. Results After 6 months of treatment,the total effective rate was 88.9% in the combination group,much higher than that（69.4%,x²=4.12,P=0.04） in TACE group;two-year survival rate was 66.7% in the combination group,much high than that（41.7%,x²=4.5,P=0.03） in the TACE group;serum AFP reduction rate was 83.3% in the combination group,significantly high than that（61.1%,P<0.05） in TACE group; No serious adverse reaction was observed in the two groups. Conclusion Cool-tip microwave ablation combined with TACE in the treatment of patients with PLC is safe and effective.

Key words: Primary liver cancer, Transcatheter arterial chemoembolization, Microwave ablation, Clinical Efficacy